Stay up to date with the latest clinical breakthroughs and highlights from major global conferences through expert-led conference coverage, concise insights and news articles. Browse premium, actionable practice pearl articles designed to support continuous development, confidence and clinical decision-making. Plus, explore free-to-view, peer-reviewed articles from our leading international journal, alongside high-quality educational activities—with patient outcomes at the forefront.
In proud collaboration with EBMT, we have captured the highlights from the recent 52nd Annual Meeting, EBMT 2026. Below, hear from Dr Anna Sureda, President of EBMT, Dr Rafael Duarte, Congress President, and other world-leading experts sharing some of the most ...
HSV infection remains a persistent and often debilitating complication in immunocompromised patients, particularly following transplantation. At EBMT26, Dr Genovefa Papanicolaou presented results from the phase III PRIOH-1 trial, highlighting the efficacy and safety of pritelivir – an oral antiviral with the potential to reshape management of acyclovir-resistant HSV.
At EBMT26, Dr Roni Shouval presented his plenary abstract: a novel approach to one of the field’s persistent challenges: scalable, real-time immune monitoring following CAR-T therapy. In this interview, Dr Shouval discusses the clinical rationale, technological framework, and future implications of this emerging methodology.
At EBMT26, Prof Florent Malard presented the final results of the phase III ARES trial evaluating fecal microbiota transfer MAAT013 in a challenging clinical setting: ruxolitinib-refractory acute graft-versus-host disease (GvHD) with gastrointestinal involvement. With few effective options and poor outcomes in this setting, the study highlights how this novel microbiome-based, immunomodulatory approach by restoring gut microbiome diversity to modulate the immune system could redefine third-line treatment.
The panel reviews treatment decision-making and monitoring for patients with chronic-phase chronic myeloid leukaemia on tyrosine kinase inhibitors.
As part of our Haematology Horizons practice pearl series, Dr Douglas Tremblay (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) explores the contemporary role and limitations of HMAs across chronic myelomonocytic leukaemia subtypes, contrasts treatment goals by patient fitness and transplant eligibility and looks ahead to emerging HMA combinations and novel agents designed specifically for CMML.
The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.
Learn more about the six highly anticipated late-breaking abstracts at ASH 2025. From in-vivo CAR-T technology and novel ITP strategies to genomic diagnostics and pragmatic perioperative trials. These data showcase fresh, innovative research, potential practice shifts and early signals that we will all want to follow closely.
Dr Thomas Jezequel, Advanced Practice Nurse at Nantes University Hospital, shares his journey in pediatric oncology and haematology, his advice for new nurses, and his vision for the future. From CAR T-cell therapy to AI, he highlights the evolving role of nurses and the importance of collaboration and research.
A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
The European Hematology Association (EHA) has released its official EHA Perspectives in Hematology reports from the 2025 Annual Congress in Milan, now available in two separate editions covering malignant and non-malignant hematology. Following strong interest in the 2024 pilot report, this expanded format offers deeper insights into scientific and clinical advances across the field.
Dr Eleni Gavriilaki, Assistant Professor of Hematology in Thessaloniki, reflects on the formative experiences and mentors that shaped her path. A touchHAEMATOLOGY Future Leader 2025, she discusses trust, clinical trials and the emotional complexity of care – and offers honest advice to the next generation of hematologists.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
CAR T-cell therapy is transforming blood cancer care, yet most eligible patients never receive it. Dr Miguel-Angel Perales outlines how the CAR T Vision Coalition plans to close this gap.
Learning points:
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Expert insights on new and emerging approaches to optimize the management of steroid-refractory cGvHD.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.